We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

5803:TSEFujikura Ltd Analysis

Data as of 2026-05-27 - not real-time

¥5,140.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fujikura Ltd. is trading well below its 20‑day SMA and 50‑day SMA, signaling short‑term weakness. The 200‑day SMA remains under the current price, indicating a longer‑term bullish backdrop. A bearish MACD crossover and a neutral RSI around the mid‑40s reinforce the near‑term downside pressure. Volume has been on an upward trend, suggesting that the recent price move is supported by market participation. The Fear & Greed Index reads Extreme Greed, reflecting heightened market optimism that may be pricing in upside beyond fundamentals.
On the fundamentals side, revenue is expanding at a robust 22% revenue growth rate and profit margins sit comfortably in the low‑teens. Return on equity exceeds 30% ROE, underscoring efficient capital deployment. The company carries a high debt‑to‑equity ratio, yet cash balances more than double total debt, providing a solid net‑cash cushion. Forward earnings are priced at a low multiple relative to the current trailing P/E, and analysts’ consensus targets imply roughly a 13% upside. The dividend yield is modest but the payout ratio is below 40%, making the dividend stream sustainable. Recent governance reforms, including a new restricted‑stock compensation plan, aim to align management incentives with shareholder value. Overall, the blend of strong growth fundamentals and a modest upside potential outweighs the short‑term technical headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price below 20‑day SMA
  • bearish MACD divergence
  • elevated volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 22% revenue growth
  • forward P/E near 17
  • analyst upside of 13%

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • high ROE over 30%
  • strong cash position net of debt
  • sustainable dividend payout

Key Metrics & Analysis

Financial Health

Revenue Growth22.00%
Profit Margin13.29%
P/E Ratio54.2
ROE31.51%
ROA13.11%
Debt/Equity17.13
P/B Ratio15.2
Op. Cash Flow¥132.9B
Free Cash Flow¥43.1B
Industry P/E30.1

Technical Analysis

TrendBullish
RSI45.9
Support¥4,156.00
Resistance¥7,933.00
MA 20¥5,901.10
MA 50¥5,291.49
MA 200¥3,489.04
MACDBearish
VolumeIncreasing
Fear & Greed Index91.16

Valuation

Fair Value¥877.34
Target Price¥5,808.86
Upside/Downside13.01%
GradeUndervalued
TypeGrowth
Dividend Yield0.71%

Risk Assessment

Beta1.22
Volatility126.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.